99 related articles for article (PubMed ID: 23530107)
1. Association of primary breast cancer of the vulva with hereditary breast and ovarian cancer.
Lamb A; Darus CJ; Skripenova S; Weisberg T; Miesfeldt S
J Clin Oncol; 2013 May; 31(13):e231-2. PubMed ID: 23530107
[No Abstract] [Full Text] [Related]
2. Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing.
De Leeneer K; Coene I; Crombez B; Simkens J; Van den Broecke R; Bols A; Stragier B; Vanhoutte I; De Paepe A; Poppe B; Claes K
Breast Cancer Res Treat; 2012 Feb; 132(1):87-95. PubMed ID: 21553119
[TBL] [Abstract][Full Text] [Related]
3. [Mutation of breast cancer susceptibility gene in ovarian cancer and its clinical significance].
Shi H; You Z; Guo Y
Zhonghua Fu Chan Ke Za Zhi; 1998 Nov; 33(11):676-8. PubMed ID: 10806719
[TBL] [Abstract][Full Text] [Related]
4. Coexisting vulvar Paget's disease and mucinous carcinoma of the breast: a case report and review of the literature.
Aroonroch R; Visetsiri Y; Wongwaisayawan S; Charakorn C; Kanchanapanjapol S; Rochanawutanon M
J Med Assoc Thai; 2012 Jun; 95(6):847-52. PubMed ID: 22774633
[TBL] [Abstract][Full Text] [Related]
5. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
Metcalfe KA; Lynch HT; Ghadirian P; Tung N; Olivotto IA; Foulkes WD; Warner E; Olopade O; Eisen A; Weber B; McLennan J; Sun P; Narod SA
Gynecol Oncol; 2005 Jan; 96(1):222-6. PubMed ID: 15589605
[TBL] [Abstract][Full Text] [Related]
6. Genetic counseling for women with breast cancer: the importance of evaluating the spouse.
Allweis TM; Sagi M; Peretz T
Clin Genet; 2004 Dec; 66(6):573-4. PubMed ID: 15521992
[No Abstract] [Full Text] [Related]
7. Analysis of the time interval between diagnoses in women with double primary breast and ovarian or primary peritoneal cancers.
Olawaiye A; Caesar L; Walsh D; Lyman M; Yeh J; Rodabaugh K; Marchetti D; Lele S; Odunsi K
Gynecol Oncol; 2004 Sep; 94(3):796-802. PubMed ID: 15350375
[TBL] [Abstract][Full Text] [Related]
8. Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?
Vineyard MA; Daniels MS; Urbauer DL; Deavers MT; Sun CC; Boerwinkle E; Bodurka DC; Gershenson DM; Crawford J; Lu KH
Gynecol Oncol; 2011 Feb; 120(2):229-32. PubMed ID: 21126756
[TBL] [Abstract][Full Text] [Related]
9. Patients with double primary tumors in the breast and ovary- clinical characteristics and BRCA1-2 mutations status.
Fishman A; Dekel E; Chetrit A; Lerner-Geva L; Bar-Am A; Beck D; Beller U; Ben-Baruch G; Piura B; Friedman E; Struewing JP; Modan B
Gynecol Oncol; 2000 Oct; 79(1):74-8. PubMed ID: 11006035
[TBL] [Abstract][Full Text] [Related]
10. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
[TBL] [Abstract][Full Text] [Related]
11. Detection of early-stage ovarian cancer by FDG-PET-CT in a patient with BRCA2-positive breast cancer.
Milam RA; Milam MR; Iyer RB
J Clin Oncol; 2007 Dec; 25(35):5657-8. PubMed ID: 18065738
[No Abstract] [Full Text] [Related]
12. [Clinical analysis of 91 cases of hereditary breast and ovarian cancer].
Li N; Wu LY; Zhang R; Zhang X; Liu LY
Zhonghua Zhong Liu Za Zhi; 2005 Apr; 27(4):245-7. PubMed ID: 15949430
[TBL] [Abstract][Full Text] [Related]
13. Gynecological tumors in hereditary nonpolyposis colorectal cancer: We know they are common--now what?
Lu KH; Broaddus RR
Gynecol Oncol; 2001 Aug; 82(2):221-2. PubMed ID: 11531270
[No Abstract] [Full Text] [Related]
14. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
15. Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients.
Thompson ER; Boyle SE; Johnson J; Ryland GL; Sawyer S; Choong DY; kConFab ; Chenevix-Trench G; Trainer AH; Lindeman GJ; Mitchell G; James PA; Campbell IG
Hum Mutat; 2012 Jan; 33(1):95-9. PubMed ID: 21990120
[TBL] [Abstract][Full Text] [Related]
16. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?
Goshen R; Chu W; Elit L; Pal T; Hakimi J; Ackerman I; Fyles A; Mitchell M; Narod SA
Gynecol Oncol; 2000 Dec; 79(3):477-81. PubMed ID: 11104623
[TBL] [Abstract][Full Text] [Related]
17. [Clinicopathological characteristics of hereditary ovarian cancer syndrome].
Zhong Y; Sheng XG; Ma ZF; Ma YB; Liu NF; Chen YT; Gao R; Wang YY; Sun L
Zhonghua Fu Chan Ke Za Zhi; 2009 Sep; 44(9):676-80. PubMed ID: 20079180
[TBL] [Abstract][Full Text] [Related]
18. Patients with a history of epithelial ovarian cancer presenting with a breast and/or axillary mass.
Karam AK; Stempel M; Barakat RR; Morrow M; Gemignani ML
Gynecol Oncol; 2009 Mar; 112(3):490-5. PubMed ID: 19101713
[TBL] [Abstract][Full Text] [Related]
19. [Hereditary predisposition for cancer of the breast and the ovary].
Lalle P; Stoppa-Lyonnet D; Mazoyer S; Rio P; Girodet C; Hardouin A; Narod SA; Sobol H; Bignon YJ
Bull Cancer; 1993 Oct; 80(10):857-65. PubMed ID: 8204923
[TBL] [Abstract][Full Text] [Related]
20. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
